Sunshine Biopharma Inc. Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax
Sunshine Biopharma Inc. (SBFM) reported Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax of -$315.63 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax · last filed 2026-08-13
- Sunshine Biopharma Inc. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax for the quarter ending 2026-06-30 was -$315.63K, a 129.10% decline year-over-year.
- Sunshine Biopharma Inc. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax for the quarter ending 2026-03-31 was -$278.00K, a 1161.50% decline year-over-year.
- Sunshine Biopharma Inc. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax for the quarter ending 2025-12-31 was $255.53K.
- Sunshine Biopharma Inc. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax for the quarter ending 2025-09-30 was -$601.63K, a 170.64% decline year-over-year.
- Sunshine Biopharma Inc. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax for fiscal 2025 was $764.65K.
- Sunshine Biopharma Inc. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax for fiscal 2024 was -$1.53M, a 385.64% decline from fiscal 2023.
- Sunshine Biopharma Inc. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax for fiscal 2023 was $534.26K, a 188.81% increase from fiscal 2022.
- Sunshine Biopharma Inc. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax for fiscal 2022 was $184.99K.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax 3 month | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax 6 month | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax 9 month | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax 12 month | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$315.63K 10-Q · filed 2026-08-13 | -$593.63K 10-Q · filed 2026-08-13 | -$338.09K derived: sum of 3 quarters · filed 2026-08-13 | -$939.72K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | -$278.00K 10-Q · filed 2026-05-13 | -$22.46K derived: sum of 2 quarters · filed 2026-05-13 | -$624.09K derived: sum of 3 quarters · filed 2026-05-13 | $460.46K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $255.53K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-03 | -$346.10K derived: sum of 2 quarters · filed 2026-04-03 | $738.46K derived: sum of 3 quarters · filed 2026-08-13 | $764.65K 10-K · filed 2026-04-03 | |
| 2025-09-30 | -$601.63K 10-Q · filed 2025-11-13 | $482.93K derived: sum of 2 quarters · filed 2026-08-13 | $509.12K 10-Q · filed 2025-11-13 | -$489.43K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $1.08M 10-Q · filed 2026-08-13 | $1.11M 10-Q · filed 2026-08-13 | $112.20K derived: sum of 3 quarters · filed 2026-08-13 | $963.84K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $26.19K 10-Q · filed 2026-05-13 | -$972.36K derived: sum of 2 quarters · filed 2026-05-13 | -$120.72K derived: sum of 3 quarters · filed 2026-05-13 | -$956.17K derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$998.55K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-03 | -$146.91K derived: sum of 2 quarters · filed 2026-04-03 | -$982.36K derived: sum of 3 quarters · filed 2026-04-03 | -$1.53M 10-K · filed 2026-04-03 | |
| 2024-09-30 | $851.64K 10-Q · filed 2025-11-13 | $16.19K derived: sum of 2 quarters · filed 2025-11-13 | -$527.51K 10-Q · filed 2025-11-13 | -$35.96K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$835.45K 10-Q · filed 2025-08-12 | -$1.38M 10-Q · filed 2025-08-12 | -$887.60K derived: sum of 3 quarters · filed 2025-08-12 | -$1.35M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$543.71K 10-Q · filed 2025-05-15 | -$52.15K derived: sum of 2 quarters · filed 2025-05-15 | -$512.66K derived: sum of 3 quarters · filed 2025-05-15 | -$20.61K derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $491.56K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $31.05K derived: sum of 2 quarters · filed 2025-04-01 | $523.10K derived: sum of 3 quarters · filed 2025-04-01 | $534.26K 10-K · filed 2025-04-01 | |
| 2023-09-30 | -$460.51K 10-Q · filed 2024-11-05 | $31.54K derived: sum of 2 quarters · filed 2024-11-05 | $42.70K 10-Q · filed 2024-11-05 | $284.45K derived: sum of 4 quarters · filed 2024-11-05 | |
| 2023-06-30 | $492.05K 10-Q/A · filed 2024-08-20 | $503.21K 10-Q/A · filed 2024-08-20 | $744.96K derived: sum of 3 quarters · filed 2024-08-20 | $699.83K derived: sum of 4 quarters · filed 2024-08-20 | |
| 2023-03-31 | $11.16K 10-Q · filed 2024-05-20 | $252.91K derived: sum of 2 quarters · filed 2024-05-20 | $207.78K derived: sum of 3 quarters · filed 2024-05-20 | $195.14K derived: sum of 4 quarters · filed 2024-05-20 | |
| 2022-12-31 | $241.75K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $196.62K derived: sum of 2 quarters · filed 2024-03-28 | $183.98K derived: sum of 3 quarters · filed 2024-03-28 | $184.99K 10-K · filed 2024-03-28 | |
| 2022-09-30 | -$45.13K 10-Q · filed 2023-11-13 | -$57.77K derived: sum of 2 quarters · filed 2023-11-13 | -$56.76K 10-Q · filed 2023-11-13 | -$62.43K derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$12.64K 10-Q · filed 2023-08-10 | -$11.64K 10-Q · filed 2023-08-10 | -$17.30K derived: sum of 3 quarters · filed 2023-08-10 | -$23.14K derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $1.01K 10-Q · filed 2023-05-10 | -$4.66K derived: sum of 2 quarters · filed 2023-05-10 | -$10.50K derived: sum of 3 quarters · filed 2023-05-10 | -$17.20K derived: sum of 4 quarters · filed 2023-05-10 | |
| 2021-12-31 | -$5.66K derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-04 | -$11.50K derived: sum of 2 quarters · filed 2023-04-04 | -$18.20K derived: sum of 3 quarters · filed 2023-04-04 | -$20.27K 10-K · filed 2023-04-04 | $20.27K 10-K · filed 2022-03-21 |
| 2021-09-30 | -$5.84K 10-Q · filed 2022-11-07 | -$12.54K derived: sum of 2 quarters · filed 2022-11-07 | -$14.60K 10-Q · filed 2022-11-07 | -$13.22K derived: sum of 4 quarters · filed 2022-11-07 | |
| 2021-06-30 | -$6.70K 10-Q · filed 2022-08-03 | -$8.77K 10-Q · filed 2022-08-03 | -$7.38K derived: sum of 3 quarters · filed 2022-08-03 | -$7.52K derived: sum of 4 quarters · filed 2022-08-03 | |
| 2021-03-31 | -$2.06K 10-Q · filed 2022-05-06 | -$678.00 derived: sum of 2 quarters · filed 2022-05-06 | -$822.00 derived: sum of 3 quarters · filed 2022-05-06 | -$346.00 derived: sum of 4 quarters · filed 2022-05-06 | |
| 2020-12-31 | $1.39K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $1.24K derived: sum of 2 quarters · filed 2022-03-21 | $1.72K derived: sum of 3 quarters · filed 2022-03-21 | $376.00 10-K · filed 2022-03-21 | |
| 2020-09-30 | -$144.00 10-Q · filed 2021-11-09 | $332.00 derived: sum of 2 quarters · filed 2021-11-09 | -$1.01K 10-Q · filed 2021-11-09 | -$1.36K derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | $476.00 10-Q · filed 2021-08-09 | -$865.00 10-Q · filed 2021-08-09 | -$1.22K derived: sum of 3 quarters · filed 2021-08-09 | -$1.34K derived: sum of 4 quarters · filed 2021-08-09 | |
| 2020-03-31 | -$1.34K 10-Q · filed 2021-05-11 | -$1.70K derived: sum of 2 quarters · filed 2021-05-11 | -$1.81K derived: sum of 3 quarters · filed 2021-05-11 | $687.00 derived: sum of 4 quarters · filed 2021-05-11 | |
| 2019-12-31 | -$356.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | -$471.00 derived: sum of 2 quarters · filed 2021-03-30 | $2.03K derived: sum of 3 quarters · filed 2021-03-30 | $1.24K 10-K · filed 2021-03-30 | |
| 2019-09-30 | -$115.00 10-Q · filed 2020-11-12 | $2.38K derived: sum of 2 quarters · filed 2020-11-12 | $1.60K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $2.50K 10-Q/A · filed 2020-08-31 | $1.71K 10-Q/A · filed 2020-08-31 | |||
| 2019-03-31 | -$785.00 10-Q · filed 2020-05-18 | ||||
| 2018-12-31 | -$4.24K 10-K · filed 2020-05-01 | ||||
| 2017-12-31 | $110.00 10-K · filed 2019-04-12 | ||||
| 2016-12-31 | -$346.00 10-K · filed 2018-04-02 | ||||
| 2015-12-31 | $740.00 10-K · filed 2017-04-17 | ||||
| 2014-12-31 | $0.00 10-K · filed 2016-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |